| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 548494000 | Having -C(=X)-, wherein X is chalcogen, attached indirectly to ring carbon of the five-membered hetero ring by an acyclic carbon or acyclic carbon chain (e.g., indole-3-acetic acid, etc.) | 19 |
| 20090012311 | PROCESS FOR THE PREPARATION OF INDOLE DERIVATIVES - A process for the preparation of indole derivatives of formula (I): | 01-08-2009 |
| 20100056803 | Pharmaceutically Acceptable Salts of Thymodepressin and Processes for their Manufacture - The present invention relates to pharmaceutically acceptable crystalline and amorphous salts of D-isoglutamyl-D-tryptophan as well as processes for their manufacture, pharmaceutical compositions comprising them, and their uses in the preparation of pharmaceutical compositions for the treatment of various conditions and/or diseases. In particular, the present invention relates to D-isoglutamyl-D-tryptophan potassium salt (1:1), D-isoglutamyl-D-tryptophan lithium salt (1:1), D-isoglutamyl-D-tryptophan calcium salt (2:1), D-isoglutamyl-D-tryptophan magnesium salt (2:1), and D-isoglutamyl-D- tryptophan organic ammonium salts (1:1). | 03-04-2010 |
| 20100160647 | ETHYNYLINDOLE COMPOUNDS - As a compound having a potent oral activity and a long-lasting cysLT | 06-24-2010 |
| 20110046396 | POLYMORPHIC FORMS OF FLUVASTATIN SODIUM AND PROCESS FOR PREPARING THE SAME - Disclosed herein are novel polymorphic forms of Fluvastatin sodium, wherein said polymorphic forms are designated as J | 02-24-2011 |
| 20130090482 | CRYSTALLINE FORMS OF 4, 4'- [4-FLUORO-7-( ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL] DIBUTANOIC ACID, 4,4'-[2-METHYL-7-( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7- ( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID - The present invention provides type C crystal of compound I, type B crystal of compound II, or type C crystal of compound III set forth in this specification. | 04-11-2013 |
| 20140005412 | TREATMENT OF ARTERIAL AGEING BY HMG CoA REDUCTASE INHIBITOR | 01-02-2014 |
| 548495000 | Acyclic nitrogen bonded directly to the acyclic carbon or acyclic carbon chain | 7 |
| 20090198072 | Methods and systems for increasing production of equilibrium reactions - Methods and systems for increasing the production of monatin in a multi-step equilibrium pathway are described. In some embodiments, a method includes adding alanine to a reactor along with one or more reactants and one or more enzymes, and producing a mixture comprising monatin and one or more intermediates. The addition of alanine results in a decreased concentration of less stable intermediates and an increased concentration of monatin. | 08-06-2009 |
| 20120264948 | MEMBRANE SEPARATION AND PURIFICATION OF MONATIN - Methods and systems for separating and purifying monatin are described. In the production of monatin, a mixture is formed which includes monatin, starting materials and intermediates. The methods and systems include a membrane having a zeta potential of from about −19 to −6 such that the membrane rejects greater than about 90% of the monatin. In some embodiments, the membrane is a nanofiltration membrane. | 10-18-2012 |
| 20130060048 | CRYSTALLINE D-ISOGLUTAMYL-D-TRYPTOPHAN AND THE MONO AMMONIUM SLAT OF D-ISOGLUTAMYL-D-TRYPTOPHAN - A process for making pure crystalline D-isoglutamyl-D-tryptophan is provided which includes the step of deprotecting essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan or its diester to yield essentially pure D-isoglutamyl-D-tryptophan. A process is also provided for the preparation of pure mono ammonium salt of D-isoglutamyl-D-tryptophan from essentially pure N-tert-butoxycarbonyl-D-isoglutamyl-D-tryptophan. D-isoglutamyl-D-tryptophan, ammonium salt ( | 03-07-2013 |
| 548496000 | The acyclic carbon or acyclic carbon chain is further unsubstituted or alkyl substituted only (e.g., tryptophane, etc.) | 4 |
| 20100274026 | Virus therapeutic drug - The object of the present invention is to provide a pharmaceutical composition for preventing or treating viral infectious diseases. The compounds of the present invention have extremely potent anti-HCV activity and HCV growth inhibitory effects, and since they also only demonstrate mild cytotoxicity in vivo, a pharmaceutical composition containing the compound of the present invention is extremely useful as an anti-HCV preventive/therapeutic agent. | 10-28-2010 |
| 548497000 | Processes | 3 |
| 20130005987 | CRYSTALLINE FORMS OF THE MONO-SODIUM SALT OF D-ISOGLUTAMYL-D-TRYPTOPHAN - The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F) of the mono-sodium salt of D-isoglutamyl-D-tryptophan. | 01-03-2013 |
| 20130072692 | PHARMACEUTICALLY ACCEPTABLE SALTS OF THYMODEPRESSIN AND PREOCESSES FOR THEIR MANUFACTURE. - The present invention relates to pharmaceutically acceptable crystalline and amorphous salts of D-isoglutamyl-D-tryptophan as well as processes for their manufacture, pharmaceutical compositions comprising them, and their uses in the preparation of pharmaceutical compositions for the treatment of various conditions and/or diseases. In particular, the present invention relates to D-isoglutamyl-D-tryptophan potassium salt (1:1), D-isoglutamyl-D-tryptophan lithium salt (1:1), D-isoglutamyl-D-tryptophan calcium salt (2:1), D-isoglutamyl-D-tryptophan magnesium salt (2:1), and D-isoglutamyl-D-tryptophan organic ammonium salts (1:1). | 03-21-2013 |
| 20130079527 | Method for Separating off Tryptophan - The invention relates to a method for separating off tryptophan from aqueous mixtures of matter, in particular fermentation broths that are already partially processed, using simulated countercurrent chromatography or simulated moving bed (SMB) chromatography, and a device for carrying out the method. | 03-28-2013 |
| 548500000 | Having -C(=X)-, wherein X is chalcogen, bonded directly to ring nitrogen of the five-membered hetero ring (e.g., indomethacin, etc.) | 1 |
| 20160159740 | INDOLE-3-CARBINOL DERIVATIVES - The present invention relates to novel stable indole-3-carbinol derivatives of Formula-I and its pharmaceutical composition and biological activity. The present invention includes compositions and methods for the treatment and prevention of conditions associated with Inflammation. | 06-09-2016 |
| 548502000 | Processes | 5 |
| 20090111999 | PROCESS FOR PRODUCING AN AROMATIC UNSATURATED COMPOUND - The present invention provides a process for producing an aromatic unsaturated compound of the formula (4) | 04-30-2009 |
| 20090259052 | PROCESSES OF PRODUCING GLUTAMIC ACID COMPOUNDS AND PRODUCTION INTERMEDIATES THEREFORE AND NOVEL INTERMEDIATE FOR THE PROCESSES - The present invention relates to processes of producing glutamic acid compounds, for example, monatin, which are useful as, for example, production intermediates for sweetener or pharmaceutical products. | 10-15-2009 |
| 20120035374 | PROCESS FOR THE PREPARATION OF FLUVASTATIN AND SALTS THEREOF - The present invention relates to an improved process for the preparation of fluvastatin or pharmaceutical acceptable salts or derivatives thereof, in particular to a one-pot process for large scale production of Fluvastatin and salts thereof in high yield and high purity and pharmaceutical preparations containing said compounds. | 02-09-2012 |
| 20120277444 | SYNTHESIS OF HYDROXYALKYL AMIDES FROM ESTERS - Hydroxyamides are synthesized from esters. A process of making hydroxyalkyl amides comprises: reacting an ester with a hydroxyalkyl amine having the formula H | 11-01-2012 |
| 20160068471 | PROCESS FOR OBTAINING IONIC AMINO ACID ESTERS - Embodiments of the present invention provide for efficient methods and processes for preparing ionic amino acid esters from a specific synthesis route. The disclosed embodiments consist of a single reaction step: reacting a natural or synthetic unprotected amino acid with an aliphatic, branched or aromatic fatty alcohol of even or odd number of carbon atoms from 6 to 20 with or without unsaturation(s), in stoichiometric amounts, in the presence of an organic acid (HX) like carboxylate, mesylate, tosylate or sulfonate, employed as catalyst and under conventional heating (CC) of 1 to 3 hours at a temperature in the range of approximately 60 to 150° C. and pressure the range of approximately 0 to approximately 250 psi; the product obtained is cooled and recrystallized from ethanol. | 03-10-2016 |
